Tumor Hyperinsulinism (Tumor HI)
Conditions
Keywords
Doege-Potter Syndrome, Ectopic insulinoma, Extra-pancreatic insulinoma, Fibrosarcoma, HCC, Hyperinsulinemia, Hypoglycemia, Hypoglycemia due to fibrosarcoma, Hypoglycemia due to HCC, Hypoglycemia due to liposarcoma, Hypoglycemia due to tumor/cancer, IGF 2 Insulinoma, IGF 2 mediated non islet cell tumor hypoglycemia, IGF-2 mediated hypoglycemia, IGF-2, Big IGF-2, IGF-oma, IGF-2-oma, Big IGF-2-oma, Insulinoma, Islet cell tumor (ICT), Liposarcoma, Neuroendocrine tumor (NET), NICTH, Non Islet Cell Tumor, Non-islet cell tumor hypoglycemia (NICTH), Paraneoplastic, Paraneoplastic hypoglycemia, PNET, Pro-insulinoma, Tumor/cancer associated hypoglycemia, Tumor/cancer induced hypoglycemia, Tumor/cancer mediated hypoglycemia, Clinical Trials for: -Insulinoma -proinsulinoma -extrapancreatic insulinoma -non-islet cell tumor -IGF-oma -HCC -Liposarcoma -Fibrosarcoma
Brief summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Detailed description
This study will include participants who are suffering from low blood sugar related symptoms (hypoglycemia) due to over-production of hormones (e.g. insulin or similar substances) by certain non-removable tumors that cannot be treated satisfactorily with available treatment. Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg. The study is divided into 3 periods: Screening (up to 4 weeks), Treatment (8 weeks) and either End of Study Follow-up (approximately up to 20 weeks after the last dose) or optional Open Label Extension (OLE) phase (up to 3 years). This study is being conducted at approximately 10-15 study sites in approximately 5 countries. The study will enroll approximately 16 participants, all with a diagnosis of tumor HI (insulin- or IGF producing tumors).
Interventions
DRUGErsodetug
Ersodetug (9 mg/kg) + SOC
Sponsors
Rezolute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist * Male or female participants of ≥18 years of age who provide written informed consent. * Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement. * Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug).
Exclusion criteria
* Evidence of active infection including human immunodeficiency virus, hepatitis B, or hepatitis C (excluding immunization patterns). * Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer), however, if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed to participate. Participation in registries and purely diagnostic studies is allowed * Any out-of-range laboratory value at screening (other than glucose) that is assessed as clinically significant by the investigator. Laboratory or radiographic abnormalities that are considered related to the underlying disease (tumor) or associated therapies and do not pose additional safety risk for study participation per investigator and Medical Monitor may be allowed. * Known allergy or sensitivity to ersodetug or any component of the drug. * Any organ condition, concomitant disease (e.g., psychiatric illness, severe alcoholism, or drug abuse, cardiac, hepatic, or kidney disease), or other abnormality that itself, or the treatment of which in the opinion of the investigator and/or Sponsor's Medical Monitor would pose an unacceptable risk to the participant in the study. * Estimated life expectancy (additional lifespan) due to underlying disease (tumor) is \<8 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants with clinically meaningful reduction in IV glucose infusion rate from baseline. | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in average daily IV glucose/dextrose infusion rate (GIR). | 8 weeks |
| Change from baseline in average daily total IV glucose delivery (g) | 8 weeks |
| Time to complete weaning off IV glucose administration after initiating ersodetug. | 8 weeks |
Countries
France, Netherlands, Switzerland, United Kingdom, United States
Contacts
CONTACTRezolute Clinical Trial
Outcome results
None listed